Abstract

Protein-based, self-assembling nanoparticles elicit superior immunity compared with soluble protein vaccines, but the immune mechanisms underpinning this effect remain poorly defined. Here, we investigated the immunogenicity of a prototypic ferritin-based nanoparticle displaying influenza hemagglutinin (HA) in mice and macaques. Vaccination of mice with HA-ferritin nanoparticles elicited higher serum antibody titers and greater protection against experimental influenza challenge compared with soluble HA protein. Germinal centers in the draining lymph nodes were expanded and persistent following HA-ferritin vaccination, with greater deposition of antigen that colocalized with follicular dendritic cells. Our findings suggest that a highly ordered and repetitive antigen array may directly drive germinal centers through a B cell-intrinsic mechanism that does not rely on ferritin-specific T follicular helper cells. In contrast to mice, enhanced immunogenicity of HA-ferritin was not observed in pigtail macaques, where antibody titers and lymph node immunity were comparable to soluble vaccination. An improved understanding of factors that drive nanoparticle vaccine immunogenicity in small and large animal models will facilitate the clinical development of nanoparticle vaccines for broad and durable protection against diverse pathogens.

Highlights

  • Engineered nanoparticles present an exciting opportunity in vaccine design allowing for the precise manipulation of antigen presentation and targeting

  • Expression and self-assembly of particles were confirmed by SDS-PAGE and transmission electron microscopy (TEM) (Supplemental Figure 1, C and D)

  • Puerto Rico/08/1934 (PR8) HA-ferritin nanoparticles self-assemble with the native trimeric influenza HA structurally intact

Read more

Summary

Introduction

Engineered nanoparticles present an exciting opportunity in vaccine design allowing for the precise manipulation of antigen presentation and targeting. Spontaneously forming virus-like particles have been harnessed for highly protective vaccines against human papilloma virus, hepatitis B, and hepatitis E [2]. Because only selected pathogens spontaneously form virus-like particles, engineered nanoparticles offer an opportunity to combine the potent vaccine immunogenicity of virus-like particles with a favorable safety profile for human use. Engineered nanoparticles carrying vaccine antigens have demonstrated superior immunogenicity over traditional subunit and whole-organism vaccines in experimental disease models of HIV [3], malaria [4], respiratory syncytial virus [5], and tuberculosis [6]. Vaccination with HA-ferritin in mice and ferrets resulted in serum antibodies of greater magnitude, potency, and breadth compared with those elicited by the licensed inactivated influenza virus vaccine

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call